Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Pharma Outbids Public Investors: Step-Ups in Biopharma Exits

This article was originally published in Start Up

Executive Summary

Biotechs exiting via selling out to Big Pharma have been averaging far higher multiples than those exiting via IPO.

You may also be interested in...



Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019

Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.

Private Equity: One Company's Surprising Route toward Value Creation

In an unusual twist, a biotech is turning to private equity for its initial institutional financing, in the belief that it will offer a better route to long-term value creation than venture capital.

Private Equity: One Company's Surprising Route toward Value Creation

In an unusual twist, a biotech is turning to private equity for its initial institutional financing, in the belief that it will offer a better route to long-term value creation than venture capital.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091294

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel